» Articles » PMID: 31897208

Identification of EP400 and TIA1 As Critical Transcription Factors Involved in Human Hepatocellular Carcinoma Relapse

Overview
Journal Oncol Lett
Specialty Oncology
Date 2020 Jan 4
PMID 31897208
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-associated mortality worldwide. Transcription factors (TFs) are crucial proteins that regulate gene expression during cancer progression; however, the roles of TFs in HCC relapse remain unclear. To identify the TFs that drive HCC relapse, the present study constructed co-expression network and identified the Tan module the most relevant to HCC relapse. Numerous hub TFs (highly connected) were subsequently obtained from the Tan module according to the intra-module connectivity and the protein-protein interaction network connectivity. Next, E1A-binding protein p400 (EP400) and TIA1 cytotoxic granule associated RNA binding protein (TIA1) were identified as hub TFs differentially connected between the relapsed and non-relapsed subnetworks. In addition, zinc finger protein 143 (ZNF143) and Yin Yang 1 (YY1) were also identified by using the plugin iRegulon in Cytoscape as master upstream regulatory elements, which could potentially regulate expression of the genes and TFs of the Tan module, respectively. The Kaplan-Meier (KM) curves obtained from KMplot and Gene Expression Profiling Interactive Analysis tools confirmed that the high expression of EP400 and TIA1 were significantly associated with shorter relapse-free survival and disease-free survival of patients with HCC. Furthermore, the KM curves from the UALCAN database demonstrated that high EP400 expression significantly reduced the overall survival of patients with HCC. EP400 and TIA1 may therefore serve as potential prognostic and therapeutic biomarkers.

Citing Articles

Bibliometric Overview on T-Cell Intracellular Antigens and Their Pathological Implications.

Ramos-Velasco B, Naranjo R, Izquierdo J Biology (Basel). 2024; 13(3).

PMID: 38534464 PMC: 10968397. DOI: 10.3390/biology13030195.


Dissecting novel mechanisms of hepatitis B virus related hepatocellular carcinoma using meta-analysis of public data.

Aljabban J, Rohr M, Syed S, Cohen E, Hashi N, Syed S World J Gastrointest Oncol. 2022; 14(9):1856-1873.

PMID: 36187396 PMC: 9516659. DOI: 10.4251/wjgo.v14.i9.1856.


A novel 16-gene alternative mRNA splicing signature predicts tumor relapse and indicates immune activity in stage I-III hepatocellular carcinoma.

Chen X, Zhang B, Lu Y, Li Z, Chen C, Yang Y Front Pharmacol. 2022; 13:939912.

PMID: 36147313 PMC: 9485890. DOI: 10.3389/fphar.2022.939912.


TIA1 Loss Exacerbates Fatty Liver Disease but Exerts a Dual Role in Hepatocarcinogenesis.

Dolicka D, Zahoran S, Correia de Sousa M, Gjorgjieva M, Sempoux C, Fournier M Cancers (Basel). 2022; 14(7).

PMID: 35406476 PMC: 8997004. DOI: 10.3390/cancers14071704.


The Multifunctional Faces of T-Cell Intracellular Antigen 1 in Health and Disease.

Fernandez-Gomez A, Izquierdo J Int J Mol Sci. 2022; 23(3).

PMID: 35163320 PMC: 8836218. DOI: 10.3390/ijms23031400.


References
1.
Han J, Meng J, Chen S, Wang X, Yin S, Zhang Q . YY1 Complex Promotes Quaking Expression via Super-Enhancer Binding during EMT of Hepatocellular Carcinoma. Cancer Res. 2019; 79(7):1451-1464. DOI: 10.1158/0008-5472.CAN-18-2238. View

2.
Ishiguchi H, Izumi H, Torigoe T, Yoshida Y, Kubota H, Tsuji S . ZNF143 activates gene expression in response to DNA damage and binds to cisplatin-modified DNA. Int J Cancer. 2004; 111(6):900-9. DOI: 10.1002/ijc.20358. View

3.
Skinkyte-Juskiene R, Kogelman L, Kadarmideen H . Transcription Factor Co-expression Networks of Adipose RNA-Seq Data Reveal Regulatory Mechanisms of Obesity. Curr Genomics. 2018; 19(4):289-299. PMC: 5930450. DOI: 10.2174/1389202918666171005095059. View

4.
Moldovan G, DAndrea A . How the fanconi anemia pathway guards the genome. Annu Rev Genet. 2009; 43:223-49. PMC: 2830711. DOI: 10.1146/annurev-genet-102108-134222. View

5.
Llovet J, Fuster J, Bruix J . The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004; 10(2 Suppl 1):S115-20. DOI: 10.1002/lt.20034. View